Quantisnow Logo
Dashboard

Avalo Therapeutics to Present at Upcoming Investor Conferences

$AVTX
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $AVTX alert in real time by email

WAYNE, Pa. and ROCKVILLE, Md., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board, will present at two upcoming investor conferences:

Stifel 2024 Healthcare Conference, New York

Monday, November 18, 2024 at 3:35 PM ET

Piper Sandler 36th Annual Healthcare Conference, New York

Wednesday, December 5, 2024 at 11:00 AM ET

Live webcasts and replays, when available, can be found under "News / Events" in the Investors section of the Avalo Therapeutics website at https://ir.avalotx.com. The archived webcasts will be available for replay for at least 30 days.

About Avalo Therapeutics

Avalo Therapeutics is a clinical stage biotechnology company focused on the treatment of immune dysregulation. Avalo's lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. Avalo also has two additional drug candidates, which include quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein). For more information about Avalo, please visit www.avalotx.com.

About AVTX-009 

AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL-1β is a central driver in the inflammatory process. Overproduction or dysregulation of IL-1β is implicated in many autoimmune and inflammatory diseases. IL-1β is a major, validated target for therapeutic intervention. There is evidence that inhibition of IL-1β could be effective in hidradenitis suppurativa and a variety of inflammatory diseases in dermatology, gastroenterology, and rheumatology.

For media and investor inquiries

Christopher Sullivan, CFO

Avalo Therapeutics, Inc.

ir@avalotx.com 

410-803-6793

or

Meru Advisors

Lauren Glaser

lglaser@meruadvisors.com 



Primary Logo

Get the next $AVTX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$AVTX

DatePrice TargetRatingAnalyst
3/25/2025$36.00Buy
Stifel
3/25/2025$23.00Buy
Jefferies
2/28/2025$48.00Overweight
Piper Sandler
2/21/2025$18.00Outperform
Wedbush
12/19/2024$40.00Buy
BTIG Research
10/24/2024Neutral
H.C. Wainwright
4/16/2024$35.00Perform → Outperform
Oppenheimer
3/3/2022$5.00 → $0.75Buy → Hold
Jefferies
More analyst ratings

$AVTX
 Press Releases

Fastest customizable press release news feed in the world

See more

  • Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board

    WAYNE, Pa. and ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical-stage biotechnology company dedicated to treating immune dysregulation, today announced the appointment of Michael Heffernan as Chairman of the Board of Directors ("Board"). Mr. Heffernan will succeed Dr. Garry Neil as Chairman of the Board. Dr. Neil will continue as a Board member and Chief Executive Officer (CEO) of the Company. "We are thrilled to welcome Michael to Avalo's Board of Directors during this pivotal time in our Company's growth," said Dr. Garry Neil, CEO of Avalo Therapeutics. "Michael's extensive experience in building and leading biopharmaceutical companie

    $AVTX
    $BHVN
    $COLL
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Avalo Reports 2024 Financial Results and Recent Business Updates

    Topline data from Phase 2 LOTUS Trial of AVTX-009 for the treatment of hidradenitis suppurativa expected in 2026 Appointed Jennifer Riley as Chief Strategy Officer Cash on hand of approximately $135 million as of December 31, 2024 expected to provide runway into at least 2027 WAYNE, Pa. and ROCKVILLE, Md., March 20, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced business updates and year-end financial results for 2024. "2024 was a transformational year for Avalo, and I am proud of the accomplishments the team has made in a short amount of time," said Dr. Garry Neil,

    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Avalo Therapeutics to Participate in Upcoming Investor Conferences

    WAYNE, Pa. and ROCKVILLE, Md., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that management will participate in the following investor conferences in March. TD Cowen 45th Annual Health Care Conference, BostonCorporate PresentationMarch 3, 2025, at 3:10 pm ET Leerink Partners Global Healthcare Conference, Miami 1x1 and small group meetings March 12, 2025 Live webcasts and replays, when available, can be found under "News / Events" in the Investors section of the Avalo Therapeutics website at https://ir.avalotx.com. The archived webcast will be available fo

    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

$AVTX
 Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$AVTX
 Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$AVTX
 Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$AVTX
 SEC Filings

See more

$AVTX
 Leadership Updates

Live Leadership Updates

See more

  • Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board

    WAYNE, Pa. and ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical-stage biotechnology company dedicated to treating immune dysregulation, today announced the appointment of Michael Heffernan as Chairman of the Board of Directors ("Board"). Mr. Heffernan will succeed Dr. Garry Neil as Chairman of the Board. Dr. Neil will continue as a Board member and Chief Executive Officer (CEO) of the Company. "We are thrilled to welcome Michael to Avalo's Board of Directors during this pivotal time in our Company's growth," said Dr. Garry Neil, CEO of Avalo Therapeutics. "Michael's extensive experience in building and leading biopharmaceutical companie

    $AVTX
    $BHVN
    $COLL
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Avalo Reports 2024 Financial Results and Recent Business Updates

    Topline data from Phase 2 LOTUS Trial of AVTX-009 for the treatment of hidradenitis suppurativa expected in 2026 Appointed Jennifer Riley as Chief Strategy Officer Cash on hand of approximately $135 million as of December 31, 2024 expected to provide runway into at least 2027 WAYNE, Pa. and ROCKVILLE, Md., March 20, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced business updates and year-end financial results for 2024. "2024 was a transformational year for Avalo, and I am proud of the accomplishments the team has made in a short amount of time," said Dr. Garry Neil,

    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Avalo Therapeutics Appoints Jennifer Riley as Chief Strategy Officer

    WAYNE, Pa. and ROCKVILLE, Md., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced the appointment of Jennifer Riley as Chief Strategy Officer, effective January 1, 2025. In this newly created role, Ms. Riley will oversee corporate strategy and commercial and product pipeline planning, with a goal of driving growth and innovation across the organization. "We are thrilled to welcome Jennifer to Avalo in the newly established role of Chief Strategy Officer," said Dr. Garry Neil, Chief Executive Officer and Chairman of the Board. "Jennifer brings extensive leadership

    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

$AVTX
 Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more